ESMO 2017: Patients with high risk prostate cancer may benefit “equally” from two new treatments

Patients with high risk prostate cancer starting long-term hormone therapy may benefit from two new treatments, according to late-breaking results from the STAMPEDE trial presented at the ESMO 2017 Congress in Madrid. Long-term hormone therapy alone has...

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2vQJrzr
via IFTTT